M
Malcolm K. Brenner
Researcher at Center for Cell and Gene Therapy
Publications - 632
Citations - 50064
Malcolm K. Brenner is an academic researcher from Center for Cell and Gene Therapy. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 109, co-authored 606 publications receiving 45233 citations. Previous affiliations of Malcolm K. Brenner include St. Jude Children's Research Hospital & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Continuous infusion of interleukin-2 in children with refractory malignancies.
Raul C. Ribeiro,Raul C. Ribeiro,Donna Rill,Paula K. Roberson,Wayne L. Furman,Wayne L. Furman,Charles B. Pratt,Charles B. Pratt,Malcolm K. Brenner,William M. Crist,William M. Crist,Ching-Hon Pui,Ching-Hon Pui +12 more
TL;DR: This is the first study of its kind to investigate the toxicity of interleukin‐2 administered by continuous infusion in children and the results suggest that it may be responsible for some of the adverse events seen in previous studies.
Journal Article
Cure of leukemia
Malcolm K. Brenner,D Pinkel +1 more
TL;DR: The challenge for the next century is to build on the increasing understanding of the molecular basis of leukemia to devise safe, cheap, and effective approaches to prevent or treat this group of diseases.
Journal ArticleDOI
CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)
Carlos A. Ramos,Mrinalini Bilgi,Claudia Gerken,Olga Dakhova,Zhuyong Mei,Bambi Grilley,Adrian P. Gee,Cliona M. Rooney,Gianpietro Dotti,Barbara Savoldo,Helen E. Heslop,Malcolm K. Brenner +11 more
TL;DR: Preliminary results of a phase 1 study of activated autologous CD30.CARTs infused in patients with relapsed/refractory CD30+ HL or NHL suggest a substantial improvement in efficacy, and indicates that infusion of T cells carrying a CD30 antigen is safe and effective after lymphodepleting chemotherapy.
Journal ArticleDOI
Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation.
Olivier Leger,Hans G. Drexler,J. E. Reittie,Lorna M. Secker-Walker,H. Grant Prentice,Malcolm K. Brenner +5 more
TL;DR: It is found that when CD3 negative effector cells are obtained from patients and cultured in vitro with interleukin 2 there is a further enhancement of cytotoxic activity against a range of target cells in the early post‐transplant period.
Journal ArticleDOI
Transfection and gene expression in normal and malignant primary B lymphocytes.
Michael Buschle,Malcolm K. Brenner,Malcolm K. Brenner,Irvin S.Y. Chen,Hans G. Drexler,Hans G. Drexler,Suzanne M. Gignac,Suzanne M. Gignac,Cliona M. Rooney,Cliona M. Rooney +9 more
TL;DR: A simple method for gene transfer into highly purified normal and malignant B lymphocytes by electroporation using a powerful expression vector containing two copies of the cytomegalovirus immediate early enhancer linked to the human T cell lymphotropic virus I promoter is described.